GE HealthCare’s Flyrcado PET Radiotracer Gains FDA Approval for Better Coronary Artery Disease Diagnosis

GE HealthCare announced that the FDA has approved Flyrcado™ (flurpiridaz F 18) injection, a groundbreaking PET myocardial perfusion imaging (MPI) agent, for detecting coronary artery disease (CAD). Flyrcado offers higher diagnostic accuracy than the widely used SPECT MPI and is…









